Literature DB >> 1688845

Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion.

P R Albert1, K A Neve, J R Bunzow, O Civelli.   

Abstract

We have previously described a cDNA which encodes a binding site with the pharmacology of the D2-dopamine receptor (Bunzow, J. R., VanTol, H. H. M., Grandy, D. K., Albert, P., Salon, J., Christie, M., Machida, C., Neve, K. A., and Civelli, O. (1988) Nature 336, 783-787). We demonstrate here that this protein is a functional receptor, i.e. it couples to G-proteins to inhibit cAMP generation and hormone secretion. The cDNA was expressed in GH4C1 cells, a rat somatomammotrophic cell strain which lacks dopamine receptors. Stable transfectants were isolated and one clone, GH4ZR7, which had the highest levels of D2-dopamine receptor mRNA on Northern blot, was studied in detail. Binding of D2-dopamine antagonist [3H]spiperone to membranes isolated from GH4ZR7 cells was saturable, with KD = 96 pM, and Bmax = 2300 fmol/mg protein. Addition of GTP/NaCl increased the IC50 value for dopamine competition for [3H]spiperone binding by 2-fold, indicating that the D2-dopamine receptor interacts with one or more G-proteins. To assess the function of the dopamine-binding site, acute biological actions of dopamine were characterized in GH4ZR7 cells. Dopamine, at concentrations found in vivo, decreased resting intra- and extracellular cAMP levels (EC50 = 8 +/- 2 nM) by 50-70% and blocked completely vasoactive intestinal peptide (VIP) induced enhancement of cAMP levels (EC50 = 6 +/- 1 nM). Antagonism of dopamine-induced inhibition of VIP-enhanced cAMP levels by spiperone, (+)-butaclamol, (-)-sulpiride, and SCH23390 occurred at concentrations expected from KI values for these antagonists at the D2-receptor and was stereoselective. Dopamine (as well as several D2-selective agonists) inhibited forskolin-stimulated adenylate cyclase activity by 45 +/- 6%, with EC50 of 500-800 nM in GH4ZR7 membranes. Dopaminergic inhibition of cellular cAMP levels and of adenylyl cyclase activity in membrane preparations was abolished by pretreatment with pertussis toxin (50 ng/ml, 16 h). Dopamine (200 nM) abolished VIP- and thyrotropin-releasing hormone-induced acute prolactin release. These data show conclusively that the cDNA clone encodes a functional dopamine-D2 receptor which couples to G-proteins to inhibit adenylyl cyclase and both cAMP-dependent and cAMP-independent hormone secretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688845

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

2.  Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.

Authors:  Allyson Booth; Tammy Trudeau; Crystal Gomez; M Scott Lucia; Arthur Gutierrez-Hartmann
Journal:  Mol Endocrinol       Date:  2014-12

Review 3.  Dopamine receptor genes: new tools for molecular psychiatry.

Authors:  H B Niznik; H H Van Tol
Journal:  J Psychiatry Neurosci       Date:  1992-10       Impact factor: 6.186

4.  Endosomal location of dopamine receptors in neuronal cell cytoplasm.

Authors:  Elizabeth C Wolstencroft; Goran Simic; Nguyen thi Man; Ian Holt; Le Thanh Lam; Paul R Buckland; Glenn E Morris
Journal:  J Mol Histol       Date:  2007-06-26       Impact factor: 2.611

5.  Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation.

Authors:  K A Neve; R L Neve; S Fidel; A Janowsky; G A Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

6.  Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system.

Authors:  Blandine Pommier; Françoise Beslot; Axelle Simon; Matthieu Pophillat; Toshimitsu Matsui; Valérie Dauge; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

7.  Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2'-iodospiperone.

Authors:  J E Leysen; W Gommeren; J Mertens; W H Luyten; P J Pauwels; M Ewert; P Seeburg
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.

Authors:  Allyson K Roof; Siwanon Jirawatnotai; Tammy Trudeau; Crystal Kuzyk; Margaret E Wierman; Hiroaki Kiyokawa; Arthur Gutierrez-Hartmann
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

9.  Mechanism of dopamine mediated inhibition of neuropeptide Y release from pheochromocytoma cells (PC12 cells).

Authors:  Guihua Cao; Alice Gardner; Thomas C Westfall
Journal:  Biochem Pharmacol       Date:  2007-01-07       Impact factor: 5.858

10.  Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?

Authors:  C L Nilsson; E Eriksson
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.